Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ib Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of VSA012 Injection in Subjects With Paroxysmal Nocturnal Hemoglobinuria Who Are Complement Inhibitor Naïve or Have Not Received Complement Inhibitor Recently and Have Persistent Anemia Despite Previous Stable Use of C5 Complement Inhibitor

NCT06848296 is registered in ClinicalTrials.gov with Bisirna Therapeutics Pte. Ltd. as lead sponsor.

NCT NCT06848296
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06848296 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ib Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of VSA012 Injection in Subjects With Paroxysmal Nocturnal Hemoglobinuria Who Are Complement Inhibitor Naïve or Have Not Received Complement Inhibitor Recently and Have Persistent Anemia Despite Previous Stable Use of C5 Complement Inhibitor
Lead sponsor
Bisirna Therapeutics Pte. Ltd.
Phase
Phase 1
Overall status
Active, not recruiting
Start date
April 15, 2025
Completion date
August 31, 2027
Enrollment
50 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

paroxysmal nocturnal hemoglobinuria (pnh)